This Article Full Text Full Text (PDF) All Versions of this Article: 20/3/661    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langenheim, J. F. Articles by Chen, W. Y. Search for Related Content PubMed PubMed Citation Articles by Langenheim, J. F. Articles by Chen, W. Y.

Two Wrongs Can Make a Right: Dimers of Prolactin and Growth Hormone Receptor Antagonists Behave as Agonists

Department of Biological Sciences (J.F.L., W.Y.C.), Clemson University, Clemson, South Carolina 29634-0326; Oncology Research Institute (J.F.L, W.Y.C), Greenville Hospital System, Greenville, South Carolina 29605-4255; and Division of Biomedical Sciences (D.T, A.M.W.), University of California, Riverside, Riverside, California 92521-0121

Address all correspondence and requests for reprints to: Wen Y. Chen, Oncology Research Institute, Greenville Hospital System, 900 West Faris Road, Greenville, South Carolina 29605-4255. E-mail: wchen{at}ghs.org.

Prolactin (PRL) and GH have two distinct binding sites (site 1 with high affinity; site 2 with low affinity) that each interact with a PRL receptor (PRLR) to form a functional receptor dimer that activates signal transduction. The G129R mutation in PRL and the G120R mutation in GH disrupt the structural integrity of site 2 such that the ligands retain the ability to bind to the first receptor with high affinity, but act as receptor antagonists. In this study, we examined the ability of monomeric and dimeric forms of these ligands, human (h) PRL and hGH, and their antagonists (hPRL-G129R and hGH-G120R) to 1) bind to PRLRs; 2) induce conformational changes in PRLRs; 3) activate signaling pathways associated with the PRLR; and 4) mediate cell proliferation in vitro. In contrast to monomeric hPRL-G129R, homodimeric hPRL-G129R induced PRLR dimerization; activated Janus family of tyrosine kinases 2/signal transducer and activator of transcription 5, Ras/Raf/MAPK kinase/Erk, and phosphatidylinositol 3-kinase/Akt signaling; and stimulated Nb2 cell proliferation. Similarly, homodimeric hGH-G120R was able to mediate signaling via the PRLR and to stimulate Nb2 cell proliferation. These experiments demonstrate that a ligand must have two functional binding sites, but that these may be site 1 plus site 2 or two site 1’s, to elicit receptor-mediated signal transduction. The size of the ligand plays less of a role in receptor activation, suggesting that the extracellular portion of the PRLR (and possibly the GH receptor) is rather flexible and can accommodate larger ligands. These findings may have implications for designing multifunctional therapeutics that target this class of cytokine receptors.

This article has been cited by other articles:

				N. Yang, J. F. Langenheim, X. Wang, J. Jiang, W. Y. Chen, and S. J. Frank Activation of Growth Hormone Receptors by Growth Hormone and Growth Hormone Antagonist Dimers: Insights into Receptor Triggering Mol. Endocrinol., April 1, 2008; 22(4): 978 - 988. [Abstract] [Full Text] [PDF]